Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate. The STIMULUS-MDS2 trial was ...

Novartis' drug segment is poised for steady cash flows ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NVS) over alleged kickbacks ...

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules Swiss pharmaceutical group Novartis said on Thursday it was winding up MorphoSys sites in Germany and the ...

Novartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have been dashed after its iscalimab candidate failed a mid-phase trial. An ...

“The Novartis collaboration presents an extraordinary opportunity to leverage our unbiased genetic screening platform and proprietary chemical libraries to address novel, high-value targets previously ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites ... its $4.8 billion deal for the oncology drug developer. Amgen charted a similar move last ...

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...